Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
Diversify Advisory Services LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 16.3% during the ...
Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...
Local AIDS experts are at odds with the United Nations Programme on HIV/AIDS (UNAIDS) over its claims that AIDS could be ...
RBC Capital analyst Brian Abrahams maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) on January 21 and set a price target ...
Hosted on MSN4d
Biotech Market Forecast: Top Trends for Biotech in 2025The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...
The leading Crohn's Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, ...
Medpage Today on MSN2d
Geriatric Assessment, QoL Correlate With OS in Older Patients With Pancreatic CancerSAN FRANCISCO -- Older patients' survival in metastatic pancreatic cancer had a significant association with baseline ...
It’s always a good sign when a couple of big deals are announced right before the conference, and this year we saw a doozie ...
An immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression versus a single drug, according to a randomized study. Median ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback